Nature Reviews Neurology

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	448
Lymphatic propagation of α-synuclein	440
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	344
Brain stimulation aids walking after spinal injury	332
Reply to ‘Perils and pitfalls of near-death experience research’	327
ANA2025 marks important milestones for the ANA and NINDS	314
Genetic insights from Parkinson disease in African and African admixed populations	308
Nociceptive action of calcitonin gene-related peptide in the trigeminovascular system	271
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	268
Neural cell state shifts and fate loss in ageing and age-related diseases	265
Global synergistic actions to improve brain health for human development	225
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	217
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	201
Disease-specific modifications of tau protein	197
Continuous levodopa production by an artificial enzyme	183
TREM2 mediates phagocytosis in glioblastoma	178
SEQUINS — a new initiative to address disparities in neurology	172
Nir Giladi (1955–2024)	165
Spinal muscular atrophy treatment in utero	158
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	155
The Digitized Memory Clinic	150
Gut macrophages involved in Parkinson disease pathogenesis	150
Mitochondrial DNA instability in Huntington disease	142
The impact of rare genetic variants on Alzheimer disease	141
Imperatives and co-benefits of research into climate change and neurological disease	134

The role of the gut microbiota in multiple sclerosis	133
Psychosis-causing lesions mapped to a hippocampal circuit	133
Ultrasound lets gene therapy into the brain	113
Brain volume is associated with cognition in MS	111
Amyloid plaques: hotspots for microglial turnover	108
Challenges of combining multimodal data in assessment of people with traumatic brain injury	105
MRI-based deep learning for TLE diagnosis	100
Gene therapy for seizures in focal cortical dysplasia	99
Neurological care for LGBT+ people	95
First trials test targeting of α-synuclein for Parkinson disease	90
The challenges of anti-tau therapeutics in Alzheimer disease	89
Author Correction: Viral pathogens increase risk of neurodegenerative disease	88
Precision neuroimmunology in multiple sclerosis — the horizon is near	86
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	85
Management of freezing of gait — mechanism-based practical recommendations	82
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	80
Neuroinflammation predicts cognitive decline in FTD	79
Motor neuron disease in Africa: a critical appraisal of the literature	79
α-Synuclein pathology as a target in neurodegenerative diseases	79
Parkinson disease pathology can originate in the kidney	76
Diversity, equity and inclusion in neurology	76
Implications of AD plasma and PET biomarker discordance	74
Food is brain medicine — relevance and translation to neurology	74
Neurosteroids alleviate seizures in rats	73
Glymphatic dysfunction in PD clinical progression	71
Addressing disparities in neurology by building the workforce in LMICs	69
A new biological classification for Parkinson disease	69
Ultrasound ablation treatment for PD	64
New IDEAS about amyloid, race and dementia disparities	61
Thalamic inflammation — a therapeutic target for brain injury?	61
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	59
Coeliac disease as a model for understanding multiple sclerosis	59
Skull bone marrow changes in multiple sclerosis	58
Spinal cord stimulation for the treatment of chronic pain	58
Newborn screening for spinal muscular atrophy: time is motor neuron	57
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	56
Is Alzheimer disease a disease?	56
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	56
From the prodromal stage of multiple sclerosis to disease prevention	56
Synaptic degeneration in Alzheimer disease	55
X-chromosome variants and PD in Latin America	50
The global and regional burden of diabetic peripheral neuropathy	50
Hypothyroidism is associated with dementia risk	49
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	48
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	48
Neurology in 2025 — reflections from Africa	47
Neurofilament light chain induces neuroinflammation	46
Oligomeric tau could spread through synapses in AD	46
Lorenzo’s House: shining a light on young-onset dementia	46
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	46

Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	45
The inter-relationship between delirium and dementia: the importance of delirium prevention	44
Global epidemiology of migraine and its implications for public health and health policy	44
Risk locus for paediatric astrocytoma identified	44
Moving towards meaningful patient and public engagement	42
Dual function of biomolecular condensates	39
α-Synuclein seeds in amyotrophic lateral sclerosis	38
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	37
Prognostic plasma biomarkers for spinal cord injury	36
CAR T cells offer hope in glioblastoma	36
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	36
New developments in guidelines for brain death/death by neurological criteria	31
Reply to ‘Recalled experiences of death: need for empirical research without prejudice’	30
Promoting collaboration at the brain–heart interface	30
Neurology in 2025 — reflections from the USA	30
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	29
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	28
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	28
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	28
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	28
Understanding the long-term neurological effects of SARS-CoV-2 infection	28
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	27
Huntington disease-like 2: insight into neurodegeneration from an African disease	27
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	27
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	27
ALS pathogenesis linked to actin barrier collapse	26
Origins and immunopathogenesis of autoimmune central nervous system disorders	26
BCAS1+ oligodendrocytes aid remyelination in MS	25
Author Correction: The complex aetiology of cerebral palsy	24
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	23
Urogenital dysfunction in neurological diseases	23
AI aces diagnosis of chronic ataxias	23
Pathogenetic mechanisms and treatment targets in cerebral malaria	23
Pharmacological rehabilitation for stroke	22
Immune gateways bypass blood–brain barrier for drug delivery in stroke	21
Serum NfL as an MS biomarker	20
AI and protein structure and function in neurological disease: relevance to disease management	20
The potential of low-field MRI for global dementia care	20
Clocking the age of Parkinson disease onset	19
Addressing disparities in the global epidemiology of stroke	19
Effects of diet on MS onset and course	19
Molecular biomarkers for vascular cognitive impairment and dementia	19
The murky waters of sex differences in post-stroke cognitive impairment	19
Nusinersen treatment response markers	18
Altered muscle cholesterol transport in ALS	17
Predictive tools in psychosis: what is ‘good enough’?	17
Nanoprobe for blood–brain barrier changes	17
Mechanistic insights into the interaction between epilepsy and sleep	16
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	15
From adaptive deep brain stimulation to adaptive circuit targeting	15
Sex and gender in neurodevelopmental conditions	15
Alzheimer disease seen through the lens of sex and gender	15
Markers help to predict dementia with Lewy bodies	14
Advancing multiple sclerosis management in older adults	14
Multidimensional MRI detects astrogliosis	14
Walking the Talk for Dementia — an experience to break down barriers	13
Author Correction: Why functional neurological disorder is not feigning or malingering	13
Limitations of neurocentric models for near-death experiences	13
Alzheimer disease in Down syndrome linked to APOE	13
Shared glial pathology in HD and schizophrenia	13
Seizure-associated changes in the Golgi apparatus	13
Evidence-based clinical care and policy making for schizophrenia	12
Psychiatric sequelae of traumatic brain injury — future directions in research	12
Parkinson disease pathology in inflammatory bowel disease	12
Multisite chronic pain: a risk factor for dementia	12
Advances in the therapeutic algorithm for myasthenia gravis	12
Artificial intelligence in epilepsy — applications and pathways to the clinic	12
Timing of hormone replacement therapy could influence Alzheimer disease risk	12
Immune mechanisms and shared immune targets in neurodegenerative diseases	12
Advancing neurogenetics in Africa: past achievements, current developments and shaping the future	12
A global view of the genetic basis of Alzheimer disease	12
Inclusion in neurological research: empowering people living with neurological diseases	12
Identification of neurons involved in schizophrenia	11
T cell–microbiome communication influences disease in MS model	11
Peripheral B cells altered in Parkinson disease	10
Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA	10
MS drug beneficial in an underrepresented group	10
PD pathology spread linked to mtDNA damage	10
Vulnerable dopamine neurons identified	10
Sensory feedback in upper limb prosthetics: advances and challenges	10

Epigenetic genes and epilepsy — emerging mechanisms and clinical applications	10
Recycling brain scans with AI	10
Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets	9
Astrocytes in the initiation and progression of epilepsy	9
Glymphatic dysfunction detected in bvFTD	9
Characteristics and mechanisms of cognitive impairment in Parkinson disease	9
27-Hydroxycholesterol propagates α-synuclein pathology in Parkinson disease	9
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	9
Addressing disparities in neurology by enhancing inclusive practice	8
Multifaceted roles of APOE in Alzheimer disease	8
Calcium dysregulation could underlie lysosomal impairment in AD	8
Oestrogen receptor variants linked to AD traits	8
Qiang Liu: addressing unmet clinical needs through neuroimmune mechanisms	7
BTK inhibitor falters in multiple sclerosis trials	7
Dementia risk scores in diverse populations	7
Stem cells show promise in Parkinson disease	7
From precision diagnosis to precision treatment in epilepsy	7
Implications of immunometabolism for smouldering MS pathology and therapy	7
Translating lifestyle interventions for optimal brain health in Africa	7
Addressing multiple sclerosis disparities in Latin American and other populations	7
EBV-specific T cells in multiple sclerosis	6
Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums	6
Functional brain networks in the evaluation of patients with neurodegenerative disorders	6
Bidirectional brain–heart interactions in health and disease	6
Engineered TREM2 antibody clears Aβ in mice	6
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis	6
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	6
Monitoring disease onset in amyotrophic lateral sclerosis	6
Oligodendrocyte progenitor cell transplant for MS	5
Neurology under the midnight sun: EAN Congress 2024 comes to Helsinki	5
Sleep and circadian disturbances in children with neurodevelopmental disorders	5
Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms	5
Brain–machine interface treats pain in rats	5
Novel plasma markers for Parkinson disease	5
Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder	5
Microglial senescence is a potential therapeutic target for Alzheimer disease	5
New CRISPR-based strategies for Alzheimer disease	5
Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept	5
Closing the loop for patients with Parkinson disease: where are we?	5
New local therapy strategies for brain tumours	4
Addressing disparities in neurology by identifying gaps in hospital care	4
‘On-demand’ gene therapy for epilepsy	4
Skin α-synuclein differentiates synucleinopathies	4
Women’s neurology: a growing subspeciality to tackle sex and gender disparities	4
Exome sequencing identifies risk variants for AD	4
Plasma biomarkers for Alzheimer disease: the road from laboratory results to clinical practice	4
Reply to: Questioning the cycad theory of Kii ALS–PDC causation	4
Finger-prick blood test for Alzheimer disease	4
Disentangling clinical and biological trajectories of neurodegenerative diseases	4
Epidemiology and characteristics of multiple sclerosis in Latin America	4
The importance of getting evidence into practice	4
Bruton tyrosine kinase inhibitors for multiple sclerosis	4
GluA2 modulator targets excitotoxicity in MS	4
Insights into the toxic effects of mutant huntingtin	4
A biomarker for mild cognitive impairment	4
WNT receptor variant linked to synaptic degeneration	4
Glioblastomas divert glucose to promote growth	3
Glyphosate and neurotoxicity — a call for scientific renewal	3
Synapse vulnerability and resilience across the clinical spectrum of dementias	3
Lost empathy in FTD linked to prefrontal hypoexcitability	3
Anne-Katrin Pröbstel: B cells, antibodies and microbiota in autoimmune disease	3
Progress and challenges in sporadic late-onset cerebellar ataxias	3
Spreading depolarization as a therapeutic target in migraine	3
Why functional neurological disorder is not feigning or malingering	3
Domestic violence and chronic traumatic encephalopathy — an under-recognized link	3
A tale of race and B cells in multiple sclerosis	3
Parkinson disease therapy: current strategies and future research priorities	3
Navigating complexities of racial disparities in Alzheimer disease biomarkers	3
Obesity-associated immune exhaustion accelerates AD pathology	3
Advances in PET imaging of protein aggregates associated with neurodegenerative disease	3
Nutritional and metabolic factors in amyotrophic lateral sclerosis	3
White matter hyperintensities — location matters	3
Autoimmune encephalitis-associated epilepsy	3
Epigenetic clocks and DNA methylation biomarkers of brain health and disease	3
Lecanemab trial in AD brings hope but requires greater clarity	3
Microglial phagocytosis in Alzheimer disease	3
The influence of MOGAD on diagnosis of multiple sclerosis using MRI	3
Building an ethnically and racially diverse neurology workforce	3
Phagocytes linked to cognitive dysfunction in neuro-HIV	3
The changing landscape of primary autoimmune neuropathies	3
Myotonic dystrophy type 1: clinical diversity, molecular insights and therapeutic perspectives	3
Environmental–genetic interactions in ageing and dementia across Latin America	3
Glioblastoma tackled with oncolytic virus	3
Veronique Miron: targeting neuroimmunology to protect myelin	3
A role for lithium in Alzheimer disease	2
SNAP25 — an early biomarker in AD and CJD	2
Clinical outcomes evolve years after traumatic brain injury	2
Clinical implications of brain asymmetries	2
FDA-approved drug promotes remyelination	2
Targeting toxic HTT1a could be the key to treating Huntington disease	2
Author Correction: A neuroscientific model of near-death experiences	2
Trans-synaptic tau propagation in progressive supranuclear palsy	2
Inverse association between age and inflammatory disease activity in multiple sclerosis	2
Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges	2
Author Correction: Pathogenetic mechanisms and treatment targets in cerebral malaria	2